Financial Performance
Sai Life Sciences Limited (NSE: SAILIFE | BSE: 544306) reported exceptional FY26 financial results with consolidated revenue growing 29.4% year-on-year to ₹21,924.92 million (₹2,192 Cr) and net profit surging 105% to ₹3,489.10 million (₹349 Cr). The standalone performance showed revenue of ₹21,532.26 million with PAT of ₹3,414.81 million. Key financial ratios improved significantly with Return on Equity at 14.61% (up from 10.92% in FY25) and Net Profit Margin expanding to 15.86% from 10.57%.
Operational Excellence and Business Growth
The company's integrated CRDMO (Contract Research, Development and Manufacturing Organization) model drove strong performance, serving 300+ global innovator clients including 19 of the top 25 global pharmaceutical companies. Operational metrics showed 34 active commercial molecules (4 added in FY26), 11 molecules in Phase III/pre-registration, and ~155 programs across multiple therapy areas. The company expanded its capabilities in peptides, ADCs, oligonucleotides, and high-potent compounds while implementing AI-enabled scientific tools across discovery and development workflows.
Capital Expenditure and Expansion
FY26 saw capital expenditure of ₹633 Cr with a planned investment of ₹1,100-1,300 Cr for FY27, focused 75% on capacity expansion and 25% on capability/technology/AI enhancements. The company operationalized a new greenfield R&D campus (Unit VIII) in IKP Hyderabad and maintained 700 KL installed manufacturing capacity across 4 global locations (India, USA, UK).
Sustainability and ESG Performance
Sai Life Sciences achieved significant sustainability milestones including EcoVadis Platinum medal (top 1% of companies assessed globally), 100% renewable energy operation at Bidar facility, and 80% renewable energy consumption across operations. The company secured SBTi-validated climate targets committing to 58.8% Scope 1+2 emissions reduction by FY35 from FY24 baseline. Environmental performance included 43% water recycling, 95.64% landfill diversion rate, and avoidance of 35,972 tCO2e emissions.
Corporate Governance and Compliance
The company maintained full compliance with SEBI LODR regulations as certified by P.S. Rao & Associates with no material non-compliances identified. Board composition included 6 directors (3 executive, 3 independent) with 16.7% gender diversity, holding 9 meetings with 98.2% average attendance. Remuneration ratios showed MD compensation at 231.25 times median employee pay, with overall median employee remuneration increasing 14%.
Workforce and Social Impact
Total workforce reached 5,224 employees + contractors with 2,607 scientists (431 PhDs/Post Doctorate). Women representation stood at 14.9% in workforce and 7.9% in leadership roles. The company maintained 88% retention rate, provided average 1,512+ training hours per employee, and reached 30,074 community beneficiaries through CSR initiatives investing ₹2.86 Cr.
Contingent Liabilities and Legal Matters
The company disclosed contingent liabilities of ₹973.10 million primarily from GST (₹859.16 million), service tax (₹12.36 million), and income tax (₹72.38 million) disputes across multiple jurisdictions. Significant GST disputes include ₹366.84 million demand from Kalaburagi, Karnataka for reverse charge on marketing support services, and ₹422.34 million disallowance of input tax credit. Subsequent to year-end, the company was named in a Public Interest Litigation before Karnataka High Court relating to environmental matters in Bidar, though no adverse orders have been passed.
Capital Structure and Shareholding
Net worth stood at ₹2,484 Cr with paid-up capital of ₹21.18 Cr (211,779,234 equity shares of ₹1 each) following a stock split during the year. Debt position remained conservative with net debt-equity ratio of 0.01. Shareholding pattern showed promoters holding 34.61%, mutual funds 27.80%, FPIs 21.17%, with 100% shares in dematerialized form.
Regulatory and Forward Outlook
The 27th Annual General Meeting is scheduled for September 17, 2026, with no dividend recommended for FY26. The company completed utilization of IPO proceeds with ₹7,200 million for debt repayment and ₹1,898.84 million for general corporate purposes. Forward-looking statements acknowledge risks including economic conditions, market dynamics, regulatory developments, and technological changes that may impact actual outcomes.